Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2019

View Archived Issues

Power to the pyrimidines

Newly identified pathway provides fat for macrophages

Neutralizing gut bacterial fragments reduces autoimmunity

New model of hemophagocytic lymphohistiocytosis points to possible therapeutic strategy

Phase III data presented for trifarotene in patients with facial and truncal acne

First patient enrolled in expansion phase of phase I/II study of tinostamustine

LGM-2605 protects from ozone-induced airway inflammation and hyperreactivity in rhesus macaques

Processa Pharmaceuticals reports preliminary safety data for PCS-499

Mirikizumab maintains response and safety in phase II study in patients with psoriasis

Improvements seen with anti-IL-13 MAb RPC-4046 in eosinophilic esophagitis patients

Striatin is a useful prognostic and diagnostic marker in patients with cirrhosis

Allergan divulges CCR-6 antagonists

Janssen Pharmaceutica discloses prostanoid EP3 receptor antagonists

BeiGene synthesizes new BTK inhibitors

MediciNova enters research collaboration regarding MN-001 for liver diseases

Medshine Discovery patents FGFR inhibitors

Sunshine Lake Pharma prepares and tests MAP3K5 inhibitors

RadioMedix and Vect-Horus to jointly develop theranostic for glioblastoma multiforme

Zealand Pharma begins dosing in phase III trial of dasiglucagon in congenital hyperinsulinism

FDA approves Spravato for treatment-resistant depression

OSE gains clearances to begin phase I study of BI-765063 in advanced solid tumors

Immutep begins dosing in phase II TACTI-002 study of Keytruda and eftilagimod alpha

Marinus initiating pivotal phase III study of oral ganaxolone in pediatric PCDH19-related epilepsy

Phase III study of givosiran in acute hepatic porphyria meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...